Last reviewed · How we verify
Anti-OX40 antibody administration — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Anti-OX40 antibody administration (Anti-OX40 antibody administration) — Providence Health & Services.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-OX40 antibody administration TARGET | Anti-OX40 antibody administration | Providence Health & Services | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-OX40 antibody administration CI watch — RSS
- Anti-OX40 antibody administration CI watch — Atom
- Anti-OX40 antibody administration CI watch — JSON
- Anti-OX40 antibody administration alone — RSS
Cite this brief
Drug Landscape (2026). Anti-OX40 antibody administration — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-ox40-antibody-administration. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab